Fate Therapeutics Inc FATE:NASDAQ

Last Price$18.44NASDAQ Closing Price as of 3:59PM ET 5/20/19
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change-0.30(1.60%)
Bid (Size)$18.30 (10)
Ask (Size)$19.99 (1)
Day Low / High$18.29 - 19.05
Volume561.9 K

View Biotechnology IndustryPeer Comparison as of 05/20/2019


Fate Therapeutics Inc ( NASDAQ )

Price: $18.44
Change: -0.30 (1.60%)
Volume: 561.9 K
3:59PM ET 5/20/2019

Rubius Therapeutics Inc ( NASDAQ )

Price: $16.39
Change: +0.72 (4.59%)
Volume: 296.0 K
4:00PM ET 5/20/2019

Aimmune Therapeutics Inc ( NASDAQ )

Price: $19.65
Change: -0.46 (2.29%)
Volume: 440.7 K
4:00PM ET 5/20/2019

OPKO Health Inc ( NASDAQ )

Price: $1.99
Change: -0.06 (2.93%)
Volume: 3.5 M
3:59PM ET 5/20/2019

Sangamo Therapeutics Inc ( NASDAQ )

Price: $9.76
Change: -0.43 (4.22%)
Volume: 1.2 M
3:59PM ET 5/20/2019

Read more news Recent News

Fate Therapeutics Says First Patient Treated With Cancer Therapy Completes Initial Safety Assessment
8:28AM ET 4/02/2019 MT Newswires

Fate Therapeutics (FATE), a clinical-stage biopharmaceutical company, said pre-market Tuesday that the first patient treated with its cancer drug FT500...

Analyst Actions: SVB Leerink Starts Fate Therapeutics At Outperform, With $20 Price Target
7:59AM ET 3/28/2019 MT Newswires

Fate Therapeutics' (FATE) average rating among analysts is a buy, with an average price target of $20. Price: 16.71, Change: -0.10, Percent Change: -0.59...

Fate Therapeutics Reports Mixed Q4; Shares Slip 2.3% After Hours
4:32PM ET 3/05/2019 MT Newswires

Fate Therapeutics (FATE) reported a net loss of $0.25 per share for Q4 from a loss of $0.29 a year earlier, but that was wider than the consensus on...

Earnings Reaction History: FATE THERAPEUTC, 60.0% Follow-Through Indicator, 6.0% Sensitive
2:46PM ET 3/05/2019 MT Newswires

Expected Earnings Release: 03/05/2019, After-hours Avg. Extended-Hours Dollar Volume: $356,938 FATE THERAPEUTC (FATE) is due to issue its quarterly...

Company Profile

Business DescriptionFate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA. View company web site for more details
Address3535 General Atomics Court
San Diego, California 92121
Number of Employees104
Recent SEC Filing05/17/20194
President, Chief Executive Officer & DirectorJ. Scott Wolchko
Chief Scientific OfficerDaniel D. Shoemaker
Vice President-Clinical DevelopmentYu Waye Chu
Senior Vice President-Corporate DevelopmentJim Beitel

Company Highlights

Price Open$18.55
Previous Close$18.74
52 Week Range$8.64 - 20.04
Market Capitalization$1.2 B
Shares Outstanding65.2 M
SectorHealth Technology
Next Earnings Announcement08/05/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.23
Beta vs. S&P 500N/A
Revenue$4.7 M
Net Profit Margin-1,138.09%
Return on Equity-54.30%

Analyst Ratings as of 05/10/2019

Consensus RecommendationConsensus Icon
Powered by Factset